anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a material for medical treatment of a polymer compound provided with bioavailability having stability for a long period of time by bonding a fatty acid macromer through a block copolymer to the polymer compound with covalent bond. CONSTITUTION:A functional group of a fatty acid macromer (e.g. one containing fatty acid at one end and amino group at the other) is linked by covalent bond to a functional group (e.g. carboxyl group) of a hydrophobic part of a block copolymer comprising a hydrophilic polymer part and a hydrophobic polymer part and then a functional group (e.g. epoxy group) of the hydrophilic part of the block copolymer is linked with covalent bond to a functional group of polymer compound to give a polymer compound having reduced blood clotting, suppressing activation of complement system and subduing platelet adhesion. A polymer shown by the formula [R<1> to R<4> are H or lower alkyl; R<5> is lower alkyl or hydroxyalkyl; X is fluorinated alkyl; m:n:o:p (weight ratio of raw material monomer)=(10-90):(0.01-60):(20-75):(0.1-20)] is preferable as the block copolymer.
In Ca- and Mg-contg. injection- or infusion solns. against magnesium tetany (hypomagnesaemia) in ruminants, the Mg is present as a basic salt or acetylglutamic acid. The solns. are used against magnesium tetany, such as field-, stable- or transport tetany in ruminants esp. cattle. They re-instate the acutely disturbed ion-equilibrium in the blood so that acute symptoms quickly disappear. They also remove excess NH3, caused by eating spring grasses, via the urea cycle. The N-acetylglutamate present stabilises the enzyme protein necessary for the reaction of excess NH3 with ornithine to form carbamylphosphate with enduring effect. The solns. are very well tolerated and have no side-effects on heart and circulation.
Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
A computer-implemented method, comprises: receiving a message including unstructured clinical data; applying a machine learning model 652 trained to determine, based at least on the unstructured clinical data including a first entity, that a second entity is the most likely entity occupying a next position in the same row or a next row in the same column of the unstructured clinical data; extracting, from structured clinical data, clinically significant data 660; and controlling, based at least on the clinically significant data, at least one medical device to perform one or more tasks. An extraction engine generates structured clinical data by populating a data structure with the values of the entities 656. Entities include a header, an organism name, a drug name, a concentration value (e.g., a minimum inhibitory concentration (MIC) value), and/or an interpretation value. Machine learning is based on a conditional random fields (CRF) model. An entity graph may be generated based on the unstructured data which comprises a horizontally aligned chain or vertically aligned chain. Actions include modifying a scheduling of activities associated with the clinical workflow and/or adjusting an allocation of resources. Medical devices may include an infusion pump, dispensing cabinet or wasting station.
The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV. The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV. Herein disclosed is a method, comprising: forming a dispersion under high shear comprising gas bubbles of an oxidant dispersed in a liquid phase, wherein the bubbles have a mean diameter of less than 1.5 micron; and contacting the dispersion with an oxidation catalyst to produce a product stream, wherein the product stream comprises a substance selected from the group consisting of dicarboxylic acid, benzoic acid, 2- methylbenzoic acid, 3- methylbenzoic acid, 4-methylbenzoic acid, and phthalic anhydride. In some cases, forming the dispersion under high shear comprises introducing the oxidant and the liquid phase into a high shear device comprising at least one rotor and at least one complementarily-shaped stator. Herein also disclosed is a system for producing a substance selected from the group consisting of dicarboxylic acid, benzoic acid, 2- methylbenzoic acid, 3- methylbenzoic acid, 4-methylbenzoic acid, and phthalic anhydride.
Most studies have focused on the effects of core stability training on injury prevention and physical performance for the lower extremities . However, little is known about its effect on upper extremity performance. Previous studies suggest that core strengthening could enhance upper extremity physical performance because it might lead to more efficient use of the extremity muscles . Core weakness in overhead athletes with shoulder pain. Insufficient power generation by the core muscles might overload the shoulder girdle to compensate for altered biomechanics during throwing, and this overload made the shoulder prone to sport injuries. A systematic review has suggested, however, that isolated core stability training cannot be the primary component of athletic performance enhancement and that the variability in exercise training protocols, testing methods, study population and sample size among the available studies leads to difficulties in understanding whether or not core stability training enhances physical performance.

There has been no study in the literature investigating the effect of progressive isolated core stability training on upper extremity performance in adolescent overhead athletes. This study therefore sought to investigate the effects of progressive isolated core stability training on shoulder internal (IR) and external rotator (ER) strength and upper extremity physical performance in female adolescent volleyball players. Hypothesized that core stability training would enhance shoulder rotator strength and upper extremity physical performance in these athletes.
PURPOSE: Intraductal prostate cancer (IDC) is linked to unfavorable oncologic outcomes, marked by distinctive cellular intrinsic pathway changes and intricate immunosuppressive microenvironments that could impact the way cancer spreads. The aim of this study was to determine whether the presence of IDC in prostate biopsy specimens obtained from patients before primary prostate cancer (PCa) treatment is associated with a lymph node metastatic propensity in prostate-specific membrane antigen (PSMA)‒positron emission tomography (PET)/CT.
MATERIALS AND METHODS: This was a cross-sectional analysis of all PCa patients undergoing a pretreatment 18F-DCFPyL-PSMA-PET/CT between January 1, 2016, and August 2021 at The Princess Margaret Cancer Centre. Outcomes were presence of any metastasis in the overall cohort, presence of lymphatic vs no metastases, and presence of lymphatic vs bone metastasis among patients who underwent PSMA-PET/CT as PCa primary staging. The associations between IDC presence on the prostate biopsy and the study outcomes were evaluated using univariable and multivariable logistic regression analyses.
RESULTS: The cohort consisted of 120 patients. IDC and cribriform pattern were observed in 55 (46%) and 48 (40%) prostate biopsies, respectively. Overall, 52 patients (43%) had evidence of metastasis. Presence of IDC on biopsy was associated with increased odds of overall metastasis (odds ratio: 2.47, 95% CI: 1.09-5.61, P = .03). Of the 52 patients with evidence of metastasis, 41 (79%) had evidence of lymphatic metastasis. Presence of IDC on biopsy was associated with significantly increased odds of lymphatic metastasis vs nonmetastases (odds ratio: 3.03, 95% CI: 1.24-7.40, P = .01).
CONCLUSIONS: The identification of IDC morphology in prostate biopsy specimens has been observed to be significantly linked with lymph node metastasis on 18F-DCFPyL-PET/CT imaging in a PCa pretreatment staging setting. We found that presence of IDC in prostate biopsy appears to be a marker for lymph node metastasis on 18F-DCFPyL-PET/CT.
Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.
Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
Common clinical manifestations include abdominal pain, abdominal distention, nausea, vomiting, delayed flatus, delayed defecation, and inability to consume orally. Postoperative ileus is an uncomfortable experience, enhances the possibility of postoperative complications, prolongs hospital stay, and increases the economic burden. Postoperative gastrointestinal function recovery is of great concern. There is currently an urgent need to improve postoperative recovery of gastrointestinal function. The mechanism of Postoperative ileus varies, including autonomic regulation, inflammatory response, gastrointestinal hormones, and postoperative use of opioid drugs. Surgical gut damage destroys the intestinal barrier, stimulates the sympathetic and parasympathetic nervous systems, and enhances the release of inflammatory factors. These factors precipitate the occurrence of Postoperative ileus. The current use of laparoscopic techniques can reduce incision size and surgical trauma, enabling careful manipulation.
FIELD: microbiology. ^ SUBSTANCE: antibacterial substance DM0507 is produced by cultivation of bacteria strain Bacillus subtilis DB9011 (FERM BP-3418), collection of supernatant of produced culture, collection of sediment produced by means of pH regulation up to 3 and less, with further extraction of sediment with ethanol. Antibacterial substance DM0507 is characterised with infrared spectrum and NMR spectrum, which are specified in dwg 1 and dwg 2 accordingly. Antibacterial substance DM0507 has antimicrobial activity against wide spectrum of microorganisms. ^ EFFECT: antimicrobial agent, food product or drink are produced. ^ 5 cl, 2 dwg, 2 tbl, 10 ex
Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to \<12 years of age - 47 mg/m\^2; 4 months to \<6 months of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Elastase is obtained from defatted pancreas by extraction with sodium acetate-acetic acid buffer at pH 4.8 to 5 followed by precipitation with (NH4)2SO4 at 48 to 55% saturation.  The precipitate is resuspended in sodium acetate-acetic acid buffer and, after demineralization, e.g. by dialysis, it is fractionally precipitated from a water-miscible alcohol/water mixture. The active precipitate is recovered, cold-centrifuged, redissolved in sodium acetate-acetic acid buffer at pH 4.7 to 5 and the solution lyophilized. All operations are carried out at a temperature below 5 DEG C.ALSO:Elastase is obtained from defatted pancreas by extraction with sodium acetate-acetic acid buffer at pH 4.8 to 5 followed by precipitation with (NH4)2SO4 at 48 to 55% saturation. The precipitate is resuspended in sodium acetateacetic acid buffer and after demineralization, e.g. by dialysis, it is fractionally precipitated from a water-miscible alchol/water mixture.  The active precipitate is recovered, cold-centrifuged, redissolved in sodium acetate-acetic acid buffer at pH 4.7 to 5 and the solution lyophilized.  All operations are carried out at a temperature below 5 DEG C.
The investigators aim to study the effects of a 24-week remote-based resistance exercise training program on cardiovascular disease risk factors, cognitive function, and quality of life in older adults living with mild cognitive impairment or Alzheimer's Disease and/or a related dementia. Data for this study will be collected at the beginning, middle, and end of the resistance training program. Measurements of resting blood pressure will be collected with an automated blood pressure monitor. Fasting blood glucose and lipids will be retrieved from the electronic medical record or from a finger stick. Waist and hip circumferences will be collected with a tape measure. Height and weight will be collected with a physician scale. Cognitive function and quality of life will be collected from interviews using the Montreal Cognitive Assessment and Short-Form (36) Health Survey. All data collected from this study will be de-identified using the "Safe-Harbor" method, which minimizes exposure of personal health information by providing each participant with a unique participant-ID and only providing access to those who are listed and approved for access privileges. Data collected for this study will also be stored on an encrypted and password- protected hard drive, and data analyzed will be performed with the Statistical Package for the Social Sciences using analyses of covariance.

When participants are enrolled in the study, he/she will be grouped on the basis of their cognitive function status from the Montreal Cognitive Assessment. All participants will then receive supervised remote-based resistance exercise training with Therabands, 3 days per week for 24 weeks. The risks of participating in exercise programs are minimal. Some of the possible risks of participating in resistance exercise include becoming tired and/or experiencing delayed onset muscle soreness, leg cramping, or muscle strain from performing resistance exercise. There are several benefits from engaging in resistance exercise programs. Participants of this study will receive health-fitness assessment at the beginning, middle, and end of the study, and as such, will benefit from being made aware of their cardiovascular disease risk factors, cognitive function, and quality of life. Other possible benefits from participation in the resistance exercise program may include improvements in muscular size and strength and/or activities of daily living.
Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling \& Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).
Antimicrobial mixtures containing specific antimicrobial diols, e.g. 1,2-dodecanediol, and specific aromatic alcohols, e.g. phenylethyl alcohol or hydrocinnamic alcohol, are provided. Such mixtures with a weight ratio of diol to aromatic alcohol of 9:1 to 1:9 have been found to exhibit a synergistic effect, i.e. a high antimicrobial activity which cannot be explained by an additive effect of the very low-activity components. Such mixtures are useful in the disinfection of hard surfaces, in the production of disinfectant cleaning preparations and in the preservation of water-based preparations of microbially degradable substances.
The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.
Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention relates to a novel gene of virus original protease inhibitor as well as the expression and the application thereof. The invention discloses a novel virus original protease inhibitor DNA sequence and an encoding protein sequence thereof, relates to a virus insect resistance key gene and enzyme and belongs to the field of gene engineering and protein engineering. The gene DNA sequence and the encoding amino acid sequence thereof are the first report of xenorhabdus nematophila. The protein expressed by the gene has remarkable inhibitory effect to prolease activity. A biological activity test shows that the protein encoded by the gene can reduce the reproduction rate of green peach aphids, improves the death of the green peach aphides and has good insecticide resistance function.The invention provides a new novel for the research of biological pesticides and transgenic zoophobous and has favorable application prospect in the field of pest control. The gene and the encoding p rotein thereof can also be applied in the field of medicament and biochemistry.
BACKGROUND: Given the strong association between high-risk HPV genotypes, such as HPV 16 and 18, and cervical cancer, this study aimed to compare the distribution of common HPV genotypes in the southwest Iranian population with those included in the available vaccines.
METHODS: Based on the sample quality, DNA was extracted from the biological samples of 8036 individuals included in the study using three different methods (automated instrument, column, and precipitation), and a total of 21 different HPV genotypes were detected using real-time PCR.
RESULTS: The majority of participants were women (> 99%), with a positive rate of HPV infection of 29.9%, in which high-risk genotypes were dominant in 84.9% cases. The highest rate of HPV infections was observed in the age ≤ 30 years (35.9%). HPV 6 and 16 were the most frequent low- and high-risk genotypes, respectively. Multi HPV infections were observed in 35% of positive samples and the highest cross infections were observed between HPV6 and 16. Co-infection with HPV 16 and 18 was observed in 21 positive samples (1%). Although vaccination is essential to reduce the outcome of HPV infections, such as cervical cancer, other frequently occurring high-risk genotypes are not included in the 9-valent vaccine.
CONCLUSION: Since the association between cervical cancer and other high-risk HPV types rather than 16 and 18 has been less studied, investigating their pathogenicity in cervical cancer is recommended. Furthermore, the new generation of HPV vaccines should contain other frequently occurring high-risk genotypes beyond those currently covered in approved vaccines.
Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.
The aim of the study is to assess the safety of an oral food challenge test with cow's milk proteins and to assess the tolerance of cow's milk proteins in children with food allergies after introducing cow's milk into the diet.

The study covers children over 12 months of age diagnosed with cow's milk allergy, treated with a non-dairy elimination diet based on extensively-hydrolyzed formulas or amino acid formulas, admitted to the Department of Pediatrics, Gastroenterology and Nutrition to conduct an open oral food challenge. In all children, after appropriate assessment and qualification (interview, physical examination, skin prick tests, results of allergen - specific immunoglobulin E (IgE), total blood count, fecal calprotectin and lactoferrin), an oral food challenge test with cow's milk will be performed. The oral food challenge test will be carried out in accordance with current standards and with child protection in the event of an adverse reactions. During the food challenge test (first 24 hours), after 2 weeks (phone survey) and 3 months after the test (visit to the Department) the frequency, severity and type of allergic reactions and cow's milk protein tolerance will be assessed. The safety of oral food challenge with cow's milk protein in children previously fed with extensively - hydrolyzed formulas or amino acid formulas will be compared. The results of allergy tests, total blood count and intestinal inflammatory markers (fecal calprotectin and fecal lactoferrin) will also be assessed before and 12 weeks after oral food challenge. The assessment of the incidence and severity of allergic reactions and tolerance of cow's milk proteins after introduction into the diet in children challenged with cow's milk proteins may help to establish guidelines on the qualifications and how to conduct an oral challenge test.
The present invention relates to novel blood sugar lowering medicine and a preparation technology thereof, wherein the blood sugar lowering medicine is a capsule containing perilla seed oil medical liquid which is prepared with a raw material of the proportion by weight portions: 500.0 portions of perilla seed oil. The mixture ratio of a capsule substrate comprises 1% of gelatin, 0.35 to 0.5 % of glycerol and 0.6 to 1% of distilled water. The soft capsule of the present invention is an appropriate dosage form, which not only can avoid the contact of the perilla seed oil and the oxygen and the water of air, but also is easy to take. The perilla seed oil capsule has the advantages of novel dosage form, stable quality, clear curative effect, good security of prepared perilla seed oil soft capsules and no toxic side effect. The perilla seed oil capsule can promote the circulation of qi, clear away inflammation, reduce grease and promote blood circulation. Clinically, besides that the perilla seed oil capsule is used for treating hyperlipoidemia, alpha linoleic acid which is a main constituent of the perilla seed oil can be converted to generate docosahexenoic acid namely DHA through in vivo metabolization. Thus, the perilla seed oil capsule has the action of lowering blood sugar to a certain extent, and is effective medicine for lowering the blood sugar. Thus, the present invention provides a new path for the application and the development of perilla seed oil capsules.